BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Baran B, Akyüz F. Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning? World J Gastroenterol 2014; 20(39): 14219-14229 [PMID: 25339808 DOI: 10.3748/wjg.v20.i39.14219]
URL: https://www.wjgnet.com/1007-9327/full/v20/i39/14219.htm
Number Citing Articles
1
Simone Coghetto Acedo, Cintia Rabelo e Paiva Caria, Érica Martins Ferreira Gotardo, José Aires Pereira, José Pedrazzoli, Marcelo Lima Ribeiro, Alessandra Gambero. Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in miceWorld Journal of Hepatology 2015; 7(24): 2551-2558 doi: 10.4254/wjh.v7.i24.2551
2
Saira Nawaz, Rajkumar Chinnadurai, Saif Al‐Chalabi, Philip Evans, Philip A. Kalra, Akheel A. Syed, Smeeta Sinha. Obesity and chronic kidney disease: A current reviewObesity Science & Practice 2023; 9(2): 61 doi: 10.1002/osp4.629
3
Vyacheslav Buko, Ilya Zavodnik, Bartlomiej Palecz, Artur Stepniak, Siarhei Kirko, Alexej Shlyahtun, Wiesława Misiuk, Elena Belonovskaya, Oxana Lukivskaya, Elena Naruta, Irina Kuzmitskaya, Tatsiana Ilyich, Bayarmaa Erdenebayar, Sluken Rakhmadieva. Betulin/2-hydroxypropyl-β-cyclodextrin inclusion complex: Physicochemical characterization and hepatoprotective activityJournal of Molecular Liquids 2020; 309: 113118 doi: 10.1016/j.molliq.2020.113118
4
Luciana M. A. Borém, João F. R. Neto, Igor V. Brandi, Deborah F Lelis, Sergio H. S. Santos. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief reviewHypertension Research 2018; 41(6): 394 doi: 10.1038/s41440-018-0040-6
5
Daniel Silva Moraes, Deborah de Farias Lelis, João Marcus Oliveira Andrade, Lara Meyer, André Luiz Sena Guimarães, Alfredo Maurício Batista De Paula, Lucyana Conceição Farias, Sérgio Henrique Sousa Santos. Enalapril improves obesity associated liver injury ameliorating systemic metabolic markers by modulating Angiotensin Converting Enzymes ACE/ACE2 expression in high-fat feed miceProstaglandins & Other Lipid Mediators 2021; 152: 106501 doi: 10.1016/j.prostaglandins.2020.106501
6
Everton Cazzo, Martinho Antonio Gestic, Murillo Pimentel Utrini, Felipe David Mendonça Chaim, Francisco Callejas-Neto, José Carlos Pareja, Elinton Adami Chaim. Bariatric surgery in individuals with liver cirrhosis: A narrative reviewRevista da Associação Médica Brasileira 2017; 63(2): 190 doi: 10.1590/1806-9282.63.02.190
7
Alessandra Ferramosca, Mariangela Di Giacomo, Vincenzo Zara. Antioxidant dietary approach in treatment of fatty liver: New insights and updatesWorld Journal of Gastroenterology 2017; 23(23): 4146-4157 doi: 10.3748/wjg.v23.i23.4146
8
Qianqian Zheng, Masaya Kawaguchi, Hayato Mikami, Pan Diao, Xuguang Zhang, Zhe Zhang, Takero Nakajima, Takanobu Iwadare, Takefumi Kimura, Jun Nakayama, Naoki Tanaka. Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and TumorsCancers 2023; 15(14): 3744 doi: 10.3390/cancers15143744
9
Yu-Tao Zhan, Hai-Ying Su, Wei An. Glycosyltransferases and non-alcoholic fatty liver diseaseWorld Journal of Gastroenterology 2016; 22(8): 2483-2493 doi: 10.3748/wjg.v22.i8.2483
10
Emanuela Esposito, Michela Campolo, Marika Cordaro, Giovanna Casili, Salvatore Cuzzocrea. Autophagy Networks in Inflammation2016; : 365 doi: 10.1007/978-3-319-30079-5_17
11
Mikhaïl Van Herck, Luisa Vonghia, Sven Francque. Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s GuideNutrients 2017; 9(10): 1072 doi: 10.3390/nu9101072
12
L. Farzin, S. Asghari, M. Rafraf, M. Asghari-Jafarabadi, M. Shirmohammadi. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver diseaseInternational Journal for Vitamin and Nutrition Research 2020; 90(3-4): 279 doi: 10.1024/0300-9831/a000528
13
Dahae Lee, Tuy An Trinh, Myoung-Sook Shin, Ki Sung Kang. Recent Advancements in Microbial Diversity2022; : 209 doi: 10.1016/B978-0-12-822368-0.00009-8
14
Nicholas W.S. Chew, Bryan Chong, Cheng Han Ng, Gwyneth Kong, Yip Han Chin, Wang Xiao, Mick Lee, Yock Young Dan, Mark D. Muthiah, Roger Foo. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseasesFrontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.971484
15
Pegah Golabi, Cameron T Locklear, Patrick Austin, Sophie Afdhal, Melinda Byrns, Lynn Gerber, Zobair M Younossi. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic reviewWorld Journal of Gastroenterology 2016; 22(27): 6318-6327 doi: 10.3748/wjg.v22.i27.6318
16
И.Р. Агабабян, Ш.Ш. Садыкова. Pleyotropic Effects of Statins Non-Alcoholic Fat Disease of the Liver Non-Alcoholic SteatohepatitisРецепт 2022; (2): 194 doi: 10.34883/PI.2022.25.2.006
17
Mikhaïl A. Van Herck, Jonas Weyler, Wilhelmus J. Kwanten, Eveline L. Dirinck, Benedicte Y. De Winter, Sven M. Francque, Luisa Vonghia. The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and ObesityFrontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.00082
18
Samir Pathak, Sanjay Pandanaboyana, Ian Daniels, Neil Smart, K.R. Prasad. Obesity and colorectal liver metastases: Mechanisms and managementSurgical Oncology 2016; 25(3): 246 doi: 10.1016/j.suronc.2016.05.021
19
Niki Katsiki, Dimitrios Tousoulis. Diabetes mellitus and comorbidities: A bad romanceHellenic Journal of Cardiology 2020; 61(1): 23 doi: 10.1016/j.hjc.2020.02.009
20
Nicholas Siebers, Melissa Palmer, Debra G. Silberg, Lee Jennings, Caleb Bliss, Patrick T. Martin. Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label StudyEuropean Journal of Drug Metabolism and Pharmacokinetics 2018; 43(1): 91 doi: 10.1007/s13318-017-0429-7
21
Seoung-Woo Lee, Su-Min Baek, Kyung-Ku Kang, A-Rang Lee, Tae-Un Kim, Seong-Kyoon Choi, Yoon-Seok Roh, Il-Hwa Hong, Sang-Joon Park, Tae-Hwan Kim, Kyu-Shik Jeong, Jin-Kyu Park. Vitamin C Deficiency Inhibits Nonalcoholic Fatty Liver Disease Progression through Impaired de Novo LipogenesisThe American Journal of Pathology 2021; 191(9): 1550 doi: 10.1016/j.ajpath.2021.05.020
22
Vasilios G Athyros. Statins for the Treatment of Non Alcoholic Fatty Liver Disease in Patients with Metabolic SyndromeJournal of Diabetes, Metabolic Disorders & Control 2016; 3(1) doi: 10.15406/jdmdc.2016.03.00057
23
Vasilios G Athyros, Konstantinos Tziomalos, Niki Katsiki, Michael Doumas, Asterios Karagiannis, Dimitri P Mikhailidis. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An updateWorld Journal of Gastroenterology 2015; 21(22): 6820-6834 doi: 10.3748/wjg.v21.i22.6820
24
Björn Carlsson, Daniel Lindén, Gabriella Brolén, Mathias Liljeblad, Mikael Bjursell, Stefano Romeo, Rohit Loomba. Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics 2020; 51(12): 1305 doi: 10.1111/apt.15738
25
Masoumeh Akhlaghi. Non-alcoholic Fatty Liver Disease: Beneficial Effects of FlavonoidsPhytotherapy Research 2016; 30(10): 1559 doi: 10.1002/ptr.5667
26
Tian Shen, Bilin Xu, Tao Lei, Lin Chen, Cuiping Zhang, Zhenhua Ni. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathwayExperimental and Therapeutic Medicine 2018;  doi: 10.3892/etm.2018.6554
27
Farah Ahsan, Federico Oliveri, Harshit K Goud, Zainab Mehkari, Lubna Mohammed, Moiz Javed, Aldanah Althwanay, Ian H Rutkofsky. Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic SteatohepatitisCureus 2020;  doi: 10.7759/cureus.10446
28
Wan-jun Zhao, Yang-ping Bian, Qiu-hui Wang, Fei Yin, Li Yin, Yong-lan Zhang, Jian-hui Liu. Blueberry-derived exosomes-like nanoparticles ameliorate nonalcoholic fatty liver disease by attenuating mitochondrial oxidative stressActa Pharmacologica Sinica 2022; 43(3): 645 doi: 10.1038/s41401-021-00681-w
29
Konstantinos Kargiotis, Vasilios G Athyros, Olga Giouleme, Niki Katsiki, Evangelia Katsiki, Panagiotis Anagnostis, Chrysoula Boutari, Michael Doumas, Asterios Karagiannis, Dimitri P Mikhailidis. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndromeWorld Journal of Gastroenterology 2015; 21(25): 7860-7868 doi: 10.3748/wjg.v21.i25.7860
30
Marcio H. Miname, Raul D. Santos. Fatty liver, inflamed blood and calcified coronary arteries: Lessons and uncertainties from the multiethnic study of atherosclerosis -commentary on the study of Al Rifai et al.Atherosclerosis 2015; 239(2): 634 doi: 10.1016/j.atherosclerosis.2015.02.041
31
Seyed Moayed Alavian, Hosein Zadi. The Relation Between Non-alcoholic Fatty Liver Disease and the Risk of Coronary Heart DiseaseMultidisciplinary Cardiovascular Annals 2022; 13(1) doi: 10.5812/mca-121262